205 related articles for article (PubMed ID: 24971999)
1. Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.
Sakurai MA; Ozaki Y; Okuzaki D; Naito Y; Sasakura T; Okamoto A; Tabara H; Inoue T; Hagiyama M; Ito A; Yabuta N; Nojima H
PLoS One; 2014; 9(6):e100124. PubMed ID: 24971999
[TBL] [Abstract][Full Text] [Related]
2. Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
Markaverich BM; Vijjeswarapu M; Shoulars K; Rodriguez M
J Steroid Biochem Mol Biol; 2010 Oct; 122(4):219-31. PubMed ID: 20558290
[TBL] [Abstract][Full Text] [Related]
3. Neonatal lethality in knockout mice expressing the kinase-dead form of the gefitinib target GAK is caused by pulmonary dysfunction.
Tabara H; Naito Y; Ito A; Katsuma A; Sakurai MA; Ohno S; Shimizu H; Yabuta N; Nojima H
PLoS One; 2011; 6(10):e26034. PubMed ID: 22022498
[TBL] [Abstract][Full Text] [Related]
4. Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
Asquith CRM; Naegeli KM; East MP; Laitinen T; Havener TM; Wells CI; Johnson GL; Drewry DH; Zuercher WJ; Morris DC
J Med Chem; 2019 May; 62(9):4772-4778. PubMed ID: 30973735
[TBL] [Abstract][Full Text] [Related]
5. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
6. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
7. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.
Jia Z; Zhang Y; Yan A; Wang M; Han Q; Wang K; Wang J; Qiao C; Pan Z; Chen C; Hu D; Ding X
Cell Death Dis; 2020 Aug; 11(8):670. PubMed ID: 32820157
[TBL] [Abstract][Full Text] [Related]
8. Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin.
Shoulars K; Rodriguez MA; Thompson T; Markaverich BM
J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):41-50. PubMed ID: 19837161
[TBL] [Abstract][Full Text] [Related]
9. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
Festuccia C; Gravina GL; Millimaggi D; Muzi P; Speca S; Ricevuto E; Vicentini C; Bologna M
Oncol Rep; 2007 Aug; 18(2):503-11. PubMed ID: 17611677
[TBL] [Abstract][Full Text] [Related]
10. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
Huang WC; Chen YJ; Li LY; Wei YL; Hsu SC; Tsai SL; Chiu PC; Huang WP; Wang YN; Chen CH; Chang WC; Chang WC; Chen AJ; Tsai CH; Hung MC
J Biol Chem; 2011 Jun; 286(23):20558-68. PubMed ID: 21487020
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer.
Liao Y; Guo Z; Xia X; Liu Y; Huang C; Jiang L; Wang X; Liu J; Huang H
J Exp Clin Cancer Res; 2019 Apr; 38(1):157. PubMed ID: 30975171
[TBL] [Abstract][Full Text] [Related]
13. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
14. Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.
Lou YF; Zou ZZ; Chen PJ; Huang GB; Li B; Zheng DQ; Yu XR; Luo XY
PLoS One; 2014; 9(5):e97719. PubMed ID: 24874286
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest.
Zhou X; Zheng M; Chen F; Zhu Y; Yong W; Lin H; Sun Y; Han X
Anat Rec (Hoboken); 2009 Aug; 292(8):1122-7. PubMed ID: 19645012
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
17. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
[TBL] [Abstract][Full Text] [Related]
18. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
Braun AH; Stark K; Dirsch O; Hilger RA; Seeber S; Vanhoefer U
Anticancer Drugs; 2005 Nov; 16(10):1099-108. PubMed ID: 16222152
[TBL] [Abstract][Full Text] [Related]
19. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
20. AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate hepatitis C virus entry and are potential drug targets.
Neveu G; Ziv-Av A; Barouch-Bentov R; Berkerman E; Mulholland J; Einav S
J Virol; 2015 Apr; 89(8):4387-404. PubMed ID: 25653444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
